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Background: There is limited data regarding the demographics and type of cardiac implant-
able electronic device (CIED) in India.
Aim: The aim of this survey was to deﬁne trends in CIED implants, which included perma-
nent pacemakers (PM), intracardiac deﬁbrillators (ICD), and cardiac resynchronization
therapy pacemakers and deﬁbrillators (CRT-P/D) devices in India.
Methods: The survey was the initiative of the Indian Society of Electrocardiology and the Indian
Heart Rhythm Society. The type of CIED used, their indications, demographic characteristics,
clinical status and co-morbidities were collected using a survey form over a period of 1 year.
Results: 2117 forms were analysed from 136 centers. PM for bradyarrhythmic indication
constituted 80% of the devices implanted with ICD's and CRT-P/D forming approximately
10% each. The most common indication for PM implantation was complete atrio-ventricular
block (76%). Single chamber (VVI) pacemakers formed 54% of implants, majority in males
(64%). The indication for ICD implantation was almost equal for primary and secondary
prevention. A single chamber ICD was most commonly implanted (65%). Coronary
artery disease was the etiology in 58.5% of patients with ICD implants. CRT pacemakers
were implanted mostly in patients with NYHA III/IV (82%), left ventricular ejection fraction
<0.35 (88%) with CRT-P being most commonly used (57%).
Conclusion: A large proportion of CIED implants in India are PM for bradyarrhythmic
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secondary prophylaxis. Most CRT devices are implanted for NYHA Class III. There is a male
predominance for implantation of CIED.
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Advances in the management of arrhythmias and heart
failure have resulted in increasing use of cardiac implantable
electronic devices (CIEDs)1 that include permanent pace-
makers (PMs), implantable cardioverter deﬁbrillatiors (ICDs),
and cardiac resynchronization therapy (CRT) pacemaker
(CRT-P), or with deﬁbrillator (CRT-D). To date, there have been
no large, multi-center data available in the use of these devices
in India. This survey was undertaken to understand the use,
indications, demographics, clinical characteristics and co-
morbidities of patients undergoing CIED implants. It is hoped
that these initial data would help to improve upon building
better databases of device implantations in India.
2. Methods
This survey was a joint initiative undertaken by the Indian
Society of Electrocardiography (ISE) and the Indian Heart
Rhythm Society (IHRS). The survey was conducted for 1 year,Fig. 1 – Geographic distribution of 136 participatifrom April 1, 2012 up to March 31, 2013. A device survey form
was circulated amongst implanting cardiologists, who volun-
teered to be a part of the survey. The details collected included
the type of implant (PM, ICD, CRT-P/D), type of device (single
chamber/dual chamber) for PM and ICDs, indications for
implantation, age, gender, New York Heart Association
(NYHA) class, associated co-morbidities, left ventricular
ejection fraction and whether it was a ﬁrst implantation or
replacement, and whether reused devices were used (Appen-
dix 1). The forms were then submitted to an independent
clinical research organization for analysis. Results of continu-
ous measurements are presented as Mean  SD (Min–Max)
and results of categorical measurements are presented as
number and percentage (%).
3. Results
A total of 2117 survey forms were collected from 136 centers
(Fig. 1) across India from implanting cardiologists.
Bradycardia pacemakers constituted the major bulk of the
CIED implants in India. Amongst the 2117 survey forms,ng centers across India in the device survey.
Fig. 2 – Types of bradycardia devices used.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 8 – 7 170bradycardia pacemakers were used in 80% of patients. 10%
were ICD implants and 10% were CRT-P/CRT-D. The age
distribution per decade of life revealed a maximum (31%)
device use in the 6th decade of life, with 22% and 20% in the 5th
and 7th decades, respectively. The gender distribution for
overall CIED implants was 64% males and 36% females. The
gender distribution (male:female) in bradycardia pacemakers,
ICD and CRT was 65:35, 85:15 and 70:30, respectively.
Bradycardia pacemakers. The commonest indication was
complete atrio-ventricular block, 76%. The device type
distribution is shown in Fig. 2. Single chamber device use
was 54%. Amongst dual chamber pacemakers, DDDR pace-
makers were used in 34% and VDD pacemakers in 11.5% of
patients. Most pacemakers were ﬁrst implants (86%) with 14%
being replacements or upgrades. No re-used bradycardia
pacemakers were implanted. 56% were in NYHA class II
and 31.1% in NYHA class I. Most (85%) patients had
LVEF > 0.45. The commonest co-morbidities in patients with
PM implantation were hypertension (28%), diabetes (15.6%),Fig. 3 – Clinical data analysis ofand coronary artery disease (CAD, 13.5%). In 27.5% of patients
no co-morbidities were noted.
ICD. Single chamber ICD was most frequently (65%) used for
prevention of sudden cardiac death from ventricular tachyar-
rhythmias. Primary prophylaxis use of ICD was seen in 52.5%.
The commonest etiology for ICD use was CAD (58.5%), followed
by idiopathic dilated cardiomyopathy (31.8%), hypertrophic
cardiomyopathy (6%), and channelopathies (3.7%). First im-
plantation of ICD was in 82.7% and remaining 17.3% were
replacements or upgrades. NYHA class II and III were noted in
48.6% and 30%, respectively. LVEF was <0.35 in 72.5% of
patients. Re-used ICDs were implanted in 2% of patients.
CRT devices. CRT-P was implanted in 57% of patients and
CRT-D in the remaining 43% patients. First implant CRT was
in 78%; 22% were either replacements or upgrades in this
group. The vast majority of these patients were in NYHA III
(71%) and NYHA IV (11%). Only 18% were in NYHA II. The QRS
width was >150 ms in 46% and between 120 and 150 ms in 50%
of patients. The LVEF was <0.35 in 88% of patients (Fig. 3).
Idiopathic DCM was present in 53% of patients with bi-
ventricular pacing devices.
4. Discussion
The Eucomed data on total number of CIED units sold in India
in the year when this survey was conducted was about 37,000.2
This survey, therefore, captured data from nearly 6% of all
CIED units implanted. The average age of patients undergoing
CIED implants in India is almost a decade younger than the
western world.3
The use of CIED has remarkably increased, all over the
world, in the last decade.4–6 In North America & Europe, CIED
implants per million populations are very high at an average of
300 patients per million.5 In the Indian context, it is a meager
25 implants per million people. This is likely due to the high
cost and self-payment in most patients; shortage of trained
cardiologists to implant these devices and probably the more
stringent use of these devices as only a life-saving measure
and not for quality of life improvement. The last point is well
highlighted by nearly 80% of bradycardia devices being for
complete AV block and only 20% for sinus node dysfunction
(affecting quality of life rather than longevity). The bradycardia
indication for pacemaker use, is not a reﬂection on the etiology patients with CRT devices.
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malignant or life-threatening bradycardias. This is completely
reverse of what is practiced in the western and other
developed nations.5 Amongst the type of devices implanted,
it is interesting to note that despite higher percentage of
complete AV block and relatively younger population, most
receive a single chamber pacemaker. This could be because of
the cost (dual chamber pacemakers cost almost twice the
single chamber pacemaker). Expertise of the operator also may
be playing a role in not implanting the atrial lead. The VDD
pacemaker seems to be underutilized. To offset the cost of dual
chamber pacemaker, either a dual lead or a single pass VDD
lead should have been used more for AV block patients. This
would help to maintain the AV synchrony and possibly lower
the chances of pacemaker syndrome, atrial ﬁbrillation, etc.
However, this needs to be evaluated on a longer follow-up in
present times. The clinical characteristics of bradycardia
pacemaker patients seem to be more or less similar to what
is seen in the rest of the world.
The overall number of ICD implants amongst all CIED was
low at 10%. This again is in contrast to the western countries.5,6
The reasons could be many, including the cost and few
electrophysiologists to implant these devices. However, there
is possibility of a referral bias, and the treating cardiologist or
physician does not perceive the beneﬁt of these devices. More
than 50% of patients with ICD implants are for primary
prophylaxis. This seeming paradox in cost-sensitive India can
be partly explained by the implanters, i.e. electrophysiologists'
(EPs) perspective. It is likely that only those patients who can
afford these devices are referred to the EPs and the latter
implement the western guidelines more frequently, which is
acceptable to the self-paying, affording patient. This also
partly explains the relatively higher number (almost one-
third) of ICDs implanted being dual chamber, not discounting
the fact that some of them may have additional pacing
requirements and hence the need for dual chamber ICDs.
Nearly 60% of ICD implants were for patients with CAD and
three-fourths of the patients had EF < 0.35 and vast majority
were in NYHA II. This is reﬂective of appropriate patient
selection by the implanters.
In the CRT devices implantation, the dominant population
was dilated cardiomyopathy with LVEF < 0.35 and in NYHA
class III, again suggesting appropriate patient selection.
However, CRT-D use was 43%, a relatively higher number as
compared to Europe.3 This might be again because of out of
pocket payment for these expensive devices; hence, only those
affording (in the overall CRT group) accept the choice of CRT-D.
One of the important social messages from this survey is
that predominantly men undergo CIED implantations. The
gender gap gets more striking with expensive devices like ICD
and CRT. In India, where there is negligible government
funding for CIED and poor coverage for health insurance, out of
pocket spending is abysmally poor for women for expensive
treatment. For the implanters, it should be emphasized that itis women with dilated cardiomyopathy who respond more
favorably to CRT.7
5. Limitations
This was a voluntary survey of relatively small number of total
CIED implants in India. Though a cross-sectional representa-
tion is likely across socio-economic strata within India, the
random sample collection might introduce some bias. Being a
one-time survey, only limited information was captured.
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